1 week Ago By ABMN Staff
Wells Fargo & Company MN increased its holdings in shares of Arcellx, Inc. ( NASDAQ:ACLX – Free Report ) by 35.7% in the 4th quarter, HoldingsChannel reports.
The firm owned 26,638 shares of the company’s stock after acquiring an additional 7,002 shares during the quarter. Wells Fargo & Company MN’s holdings in Arcellx were worth $2,043,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Several other institutional investors also recently bought and sold shares of ACLX.
Lord Abbett & CO. LLC raised its holdings in Arcellx by 2.1% in the 3rd quarter.
Lord Abbett & CO. LLC now owns 891,848 shares of the company’s stock worth $74,478,000 after purchasing an additional 18,004 shares during the period. Avanza Fonder AB acquired a new position in shares of Arcellx during the 4th quarter valued at about $184,000.
KBC Group NV grew its stake in shares of Arcellx by 37.3% in the 4th quarter. KBC Group NV now owns 1,388 shares of the company’s stock valued at $106,000 after buying an additional 377 shares during the period.
China Universal Asset Management Co. Ltd. grew its holdings in shares of Arcellx by 10.
9% during the 4th quarter. China Universal Asset Management Co. Ltd.
now owns 11,466 shares of the company’s stock worth $879,000 after purchasing an additional 1,127 shares during the period. Finally, Legato Capital Management LLC increased its position in shares of Arcellx by 36.1% during the fourth quarter.
Legato Capital Management LLC now owns 5,999 shares of the company’s stock valued at $460,000 after acquiring an additional 1,591 shares during the last quarter. 96.03% of the stock is currently owned by hedge funds and other institutional investors.
Arcellx Stock Down 0.4 % ACLX opened at $63.71 on Friday.
The firm has a market cap of $3.50 billion, a P/E ratio of -89.73 and a beta of 0.
33. The business has a fifty day simple moving average of $64.77 and a 200-day simple moving average of $74.
88. Arcellx, Inc. has a 52 week low of $47.
88 and a 52 week high of $107.37. Insider Buying and Selling In related news, insider Rami Elghandour sold 38,300 shares of the stock in a transaction on Wednesday, February 26th.
The shares were sold at an average price of $62.02, for a total value of $2,375,366.00.
Following the transaction, the insider now directly owns 149,186 shares of the company’s stock, valued at $9,252,515.72. This trade represents a 20.
43 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website . Also, Director Kavita Patel sold 1,500 shares of Arcellx stock in a transaction that occurred on Tuesday, April 8th.
The stock was sold at an average price of $57.50, for a total value of $86,250.00.
The disclosure for this sale can be found here . Over the last quarter, insiders sold 54,455 shares of company stock worth $3,408,458. Corporate insiders own 6.
24% of the company’s stock. Arcellx Company Profile ( Free Report ) Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
Featured Articles Want to see what other hedge funds are holding ACLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcellx, Inc. ( NASDAQ:ACLX – Free Report ).
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter ..
